Texas is currently home to 4857 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Houston, Dallas, San Antonio and Austin. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
DBS of the SCC for the Treatment of Medically Refractory CLBP
Recruiting
The purpose of this study is to evaluate the feasibility and preliminary efficacy of deep brain stimulation of the subgenual cingulate cortex for the treatment of chronic medically-refractory low back pain using a randomized double-blind crossover design.
Gender:
ALL
Ages:
Between 40 years and 75 years
Trial Updated:
02/14/2025
Locations: University of Texas Southwestern Medical Center, Dallas, Texas
Conditions: Chronic Low-back Pain
Continuous Positive Airway Pressure (CPAP) for Sleep Apnea in Pregnancy
Recruiting
A randomized controlled trial of 1,500 women to assess whether treatment of obstructive sleep apnea with continuous positive airway pressure (CPAP) in pregnancy will result in a reduction in the rate of hypertensive disorders of pregnancy.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
02/14/2025
Locations: University of Texas Medical Branch, Galveston, Texas
Conditions: Obstructive Sleep Apnea of Adult, Preeclampsia, Obstetrical Complications
Protocol for Collecting, Banking and Distributing Human Tissue Samples: St. Jude Children's Research Hospital Tissue Resources Core Facility
Recruiting
The aims of this protocol are: to collect and store diseased and normal tissue and body fluid samples from new and returning patients at St. Jude Children's Research Hospital (SJCRH), affiliated sites and collaborating institutions; to collect and store samples from relatives of SJCRH patients; to collect and store retrospective and prospective pertinent corresponding clinical and laboratory data on disease characterization, treatment, and outcome; and to serve as a source of human biological sa... Read More
Gender:
ALL
Ages:
All
Trial Updated:
02/14/2025
Locations: Cook Children's Medical Center, Fort Worth, Texas
Conditions: Normal and Diseased Tissue and Body Fluids Samples
Phase I Trial of 5-Fluorouracil (5FU) -Based Therapy in Combination With Hydroxytyrosol (HT) in Patients With Advanced or Metastatic Colorectal Cancer
Recruiting
This is a phase I study investigating the safety and antitumor activity of 5FU-based therapy (FOLFIRI/FOLFOX + Biologics) in combination with Hydroxytyrosol (HT) as a treatment for patients with advanced or metastatic colorectal cancer. Patients will receive: 1 capsule of HT 25 mg daily for 2 weeks before beginning 5FU-based therapy (FOLFIRI/FOLFOX + Biologics), 1 capsule of HT (25 mg) daily for 2 weeks while receiving the FOLFIRI/FOLFOX + Biologics, until sign of disease progression. The pres... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/13/2025
Locations: Houston Methodist., Houston, Texas
Conditions: Advanced or Metastatic CRC
Phase 1 Trial of BTM-3566 in Relapsed/Refractory Mature B Cell Lymphomas
Recruiting
The goal of this clinical trial is to learn if BMT-3566 can safety be given to adult patients with relapsed or refractory mature b cell lymphomas. It will also learn how well BTM-3566 works to treat relapsed or refractory mature b cell lymphomas. The main questions it aims to answer are: What are the side effects of BTM-3566 at different doses? What are the levels of BTM-3566 in the blood at different timepoints around dosing? What is the clinical benefit of BTM-3566 in treating cancer (i.e. ho... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/13/2025
Locations: MD Anderson Cancer Center, Houston, Texas
Conditions: Lymphoma, B-Cell
A Study of Barzolvolimab in Patients With Atopic Dermatitis
Recruiting
The purpose of this study is to assess the efficacy and safety of barzolvolimab in adults with Atopic Dermatitis
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/13/2025
Locations: Center for Clinical Studies, Webster, Texas
Conditions: Atopic Dermatitis
A Trial Investigating Lu AG09222 With Ubrogepant in Participants With Migraine
Recruiting
The main goal of this trial is to learn more about the safety and tolerability of Lu AG09222 when taken together with ubrogepant. This includes looking for any new or worsening medical issues the participants have with the treatment. During the trial, participants with migraine will receive ubrogepant oral tablets and an injection of either Lu AG09222 or a placebo.
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
02/13/2025
Locations: Future Search Trials, Austin, Texas
Conditions: Migraine
Ivosidenib (IVO) Monotherapy and Azacitidine (AZA) Monotherapy in Patients With Hypomethylating Agent (HMA) Naive Myelodysplastic Syndromes (MDS) With an IDH1 Mutation
Recruiting
This study will enroll participants with myelodysplastic syndromes (MDS) with an Isocitrate dehydrogenase protein, 1 (IDH1) mutation, who have not received treatment with a hypomethylating agent previously. Participants will be randomized to receive either ivosidenib (IVO) alone or azacitidine (AZA) alone. IVO will be administered daily throughout the 28-day treatment cycle and AZA will be administered for the first 7 days of each 28-day cycle. Study visits will be conducted every week during Cy... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/13/2025
Locations: University of Texas UT Southwestern Comprehensive Cancer Center, Dallas, Texas
Conditions: Hypomethylating Agent (HMA) Naive Myelodysplastic Syndromes (MDS), Myelodysplastic Syndromes (MDS)
Dronabinol as an Adjunct for Reducing Pain
Recruiting
This exploratory, proof-of-concept study is a double-blind (participants and investigators will be blinded), placebo-controlled, randomized, two-arm clinical trial of Marinol \[dronabinol, synthetic Δ9-tetrahydrocannabinol (THC)\] for chronic low back pain (cLBP) with a 2:1 allocation ratio. Up to 75 subjects will be enrolled in this pilot study and randomized to receive doses of THC (up to 30 mg/day), orally, over 8 weeks. This study will be conducted at a single site; it does not include any s... Read More
Gender:
ALL
Ages:
Between 18 years and 64 years
Trial Updated:
02/13/2025
Locations: Michael E Debakey VA Medical Center, Houston, Texas
Conditions: Low Back Pain, Chronic Pain, Back Injuries
Phase I/II Study of AD-PluReceptor Plus Tafasitamab-cxix and Lymphodepleting Chemotherapy in Patients With Autoimmune Disorders
Recruiting
The goal of Safety Lead-In is to confirm the safety of tafasitamab when given to patients with SSc, SLE, and LN. The goal of Phase 1 is to find the recommended dose of AD-PluReceptor-NK cells in combination with tafasitamab and lymphodepleting chemotherapy that can be given to patients with the disease. The goal of Phase 2 is to learn if the dose of AD-PluReceptor-NK cells found in Phase 1 in combination with tafasitamab and lymphodepleting chemotherapy can help to control the disease.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/13/2025
Locations: MD Anderson Cancer Center, Houston, Texas
Conditions: Autoimmune Disorders, Systemic Sclerosis
A Phase 3 Study of UGN-103 for Treatment of Patients With Low-grade Intermediate-risk Non-muscle Invasive Bladder Cancer
Recruiting
This Phase 3, single-arm, multicenter study will evaluate the efficacy and safety of UGN-103, a novel formulation of UGN-102, instilled in the urinary bladder of patients with low-grade non-muscle invasive bladder cancer (LG-NMIBC).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/13/2025
Locations: Houston Metro Urology (HMU) - Southwest Location, Houston, Texas
Conditions: Bladder Cancer, Urothelial Carcinoma, Urothelial Carcinoma Bladder
Exenatide For Reducing the Reinforcing Effects of Cocaine
Recruiting
This study will determine the safety and tolerability of exenatide (Bydureon®) as a pharmacotherapy for cocaine use disorder. An inpatient human laboratory study will be conducted in which the self-administration of cocaine, as well as the subjective and physiological effects of cocaine, are evaluated during maintenance on placebo and exenatide. Although exenatide (Bydureon) is approved by the Food and Drug Administration (FDA) for the treatment of type 2 diabetes, it has not been approved by t... Read More
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
02/13/2025
Locations: Michael E. DeBakey VA Medical Center, Houston, Texas
Conditions: Cocaine Use Disorder